Crossject expands executive board to five with Lacombe, Morin, Seltz appointments

• Crossject expanded its Executive Board to five members, appointing Olivier Lacombe, Didier Morin, Lionel Seltz with immediate effect.
• Lacombe joined in 2021, bringing 21 years in pharmaceutical development from Fournier, Abbott, Solvay, Inventiva.
• Morin joined in 2023, bringing 30 years in industrial operations from IDS, Axess Vision.
• Seltz joined in January 2026, bringing 25 years in life sciences finance from Cegedim, IQVIA/IMS Health, Mars Group.
• Crossject US appointed David Pudwill as VP, Regulatory & Scientific Affairs; he brings about 20 years’ experience, including nine at the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crossject SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250130OMX_____CNEWS_EN_GNW1001274472_en) on September 25, 2026, and is solely responsible for the information contained therein.